Black Diamond Therapeutics, Inc. (BDTX) Latest Filing Signal

Latest Filing: 10-K  |  Filed Mar 16, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Black Diamond Therapeutics, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Black Diamond Therapeutics, Inc.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Turned Positive

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Black Diamond Therapeutics, Inc. actually do?
Answer:
Black Diamond Therapeutics is a clinical-stage oncology company focused on developing MasterKey therapies designed to target families of oncogenic mutations in cancer patients. Leveraging its proprietary MAP drug discovery engine, the company aims to create precision medicines that overcome resistance and minimize toxicities. Its lead program, silevertinib, a brain-penetrant EGFR MasterKey inhibitor, is being evaluated in Phase 2 trials for non-small cell lung cancer (NSCLC) and is slated for a Phase 2 trial in glioblastoma (GBM) in Q2 2026. The company has outlicensed its BDTX-4933 program to Servier Pharmaceuticals LLC. Black Diamond Therapeutics operates as a single segment, with its primary focus on advancing its pipeline through clinical development.
Question:
What are Black Diamond Therapeutics, Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by upfront payments, milestone payments, and royalties from licensing agreements, such as the agreement with Servier for BDTX-4933. The company does not currently generate product revenue.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required